The earnings call reflected a generally positive outlook with strong growth in the bioprocessing segment and solid financial performance, despite challenges in the life sciences segment and the China market, as well as uncertainties due to global trade tensions.

Company Guidance

During the second quarter 2025 earnings call, Danaher Corporation highlighted its strong financial performance, driven by a 1.5% core revenue growth and sales of $5.9 billion. The adjusted operating profit margin was 27.3%, and the company generated $1.1 billion in free cash flow for the quarter. Key financial metrics included an adjusted diluted net earnings per share increase of approximately 5% year-over-year to $1.80, and a year-to-date free cash flow to net income conversion ratio of 143%. Despite global trade tensions, the company maintained its full-year core revenue growth expectation of approximately 3% and raised its full-year adjusted diluted net EPS guidance to a range of $7.70 to $7.80. Bioprocessing showed promising trends with high single-digit growth expectations for the second half, supported by robust demand for consumables and a consistent order book. Life sciences saw a modest recovery in pharma spending, while diagnostics experienced stable core revenue growth. Danaher remains focused on innovation and long-term growth, with significant investments in new product launches and technology advancements across its portfolio.

Strong Bioprocessing Growth

Core revenue in the biotechnology segment increased by 6%, with bioprocessing up high single digits, driven by double-digit growth in consumables due to robust demand for commercialized therapy.

Solid Financial Performance

Sales were $5.9 billion in the second quarter with a 1.5% core revenue growth. Adjusted diluted net earnings per share rose by approximately 5% year-over-year to $1.80. Free cash flow was $1.1 billion for the quarter.

New Product Launches

Important new product and technology launches in biotechnology, life sciences, and diagnostics, including new protein A resins and the Xenotov 8600 mass spectrometer, reinforcing competitive positioning.

Partnership with AstraZeneca

A new partnership with AstraZeneca was announced to develop diagnostic tools for precision medicine, leveraging Danaher Centers for enabling precision medicine.

Positive Momentum in Diagnostics

Core revenue increased by 2% in diagnostics, with non-respiratory revenue growing by double digits, driven by sexual health, virology, and hospital-acquired infections tests.

Danaher (DHR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DHR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 28, 2025	2025 (Q3)	1.72 / -	1.71	―	―	―
Jul 22, 2025	2025 (Q2)	1.64 / 1.80	1.72	4.65% (+0.08)
Apr 22, 2025	2025 (Q1)	1.63 / 1.88	1.92	-2.08% (-0.04)
Jan 29, 2025	2024 (Q4)	2.16 / 2.14	2.09	2.39% (+0.05)
Oct 22, 2024	2024 (Q3)	1.57 / 1.71	2.02	-15.35% (-0.31)
Jul 23, 2024	2024 (Q2)	1.57 / 1.72	1.817	-5.34% (-0.10)
Apr 23, 2024	2024 (Q1)	1.72 / 1.92	2.092	-8.22% (-0.17)
Jan 30, 2024	2023 (Q4)	1.91 / 2.09	2.544	-17.85% (-0.45)
Oct 24, 2023	2023 (Q3)	1.81 / 2.02	2.269	-10.97% (-0.25)
Jul 25, 2023	2023 (Q2)	1.78 / 1.82	2.446	-25.72% (-0.63)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DHR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 22, 2025	$188.07	$189.91	+0.98%
Apr 22, 2025	$184.67	$191.76	+3.84%
Jan 29, 2025	$247.07	$223.03	-9.73%
Oct 22, 2024	$270.93	$260.16	-3.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.